{"title":"Management of acute hyperkalaemia: evidence, practice and pitfalls.","authors":"Samuel Ford, Anna Zipf, Julian Williams","doi":"10.18773/austprescr.2026.040","DOIUrl":"10.18773/austprescr.2026.040","url":null,"abstract":"<p><p>Acute hyperkalaemia is a medical emergency requiring rapid clinical evaluation. Point-of-care blood gas analysis may overestimate serum potassium concentration and should be confirmed with a laboratory sample unless urgent treatment is required. When ECG (electrocardiogram) changes are present, immediate cardiac protection is a priority. Current guidelines recommend administering intravenous 10% calcium gluconate to restore cardiac conduction velocity. Intravenous insulin rapidly shifts potassium into cells. It is given with intravenous dextrose to reduce the risk of hypoglycaemia. A reduced insulin dose can be considered in patients with significant kidney dysfunction. Salbutamol shifts potassium into cells and has a synergistic effect with insulin. Nebulised salbutamol administration offers similar efficacy to intravenous delivery with fewer adverse effects. The routine use of intravenous sodium bicarbonate or oral potassium binders is not recommended for immediate lowering of serum potassium in acute hyperkalaemia. Sodium bicarbonate should be reserved as an adjunctive treatment for patients with concurrent metabolic acidosis. Post-acute care focuses on addressing reversible triggers and, once hyperkalaemia resolves, restarting important drugs that can increase potassium concentrations, if their benefit outweighs the risk (e.g. renin-angiotensin-aldosterone system inhibitors).</p>","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"49 5","pages":"194-200"},"PeriodicalIF":4.3,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13696857/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149277331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Hepatitis B update: enabling progress towards elimination.","authors":"Jane Davies, Marilou Capati, Nicole Allard","doi":"10.18773/austprescr.2026.043","DOIUrl":"10.18773/austprescr.2026.043","url":null,"abstract":"<p><p>Hepatitis B is a common vaccine-preventable and treatable condition. Chronic hepatitis B is often asymptomatic and can be missed if the diagnosis is not actively considered. The World Health Organization and the Australian Government have committed to eliminate hepatitis B as a public health threat by 2030. The tools required to achieve this are available: an effective vaccine, accurate blood tests for diagnosis and monitoring, effective antiviral treatments and access to ultrasound to enable early diagnosis of hepatocellular carcinoma. Risk-based testing approaches are not effective enough to enable Australia to achieve elimination targets; hence, the <i>Fourth National Hepatitis B Strategy 2025-2030</i> calls for population-wide testing to identify hepatitis B status. Chronic hepatitis B is a lifelong disease that requires long-term monitoring and follow-up irrespective of the stage of disease or whether an individual is taking antiviral treatment. Most healthcare for people living with chronic hepatitis B can be provided in primary care. All medical practitioners and authorised nurse practitioners can now prescribe antiviral therapy for hepatitis B; additional accreditation is no longer required. Holistic care includes the provision of resources in a person's preferred language, peer and cultural support workers, access to a long-term effective model of care, and appropriate monitoring. Continuity of healthcare providers is desirable and an important enabler of sustained engagement in care.</p>","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"49 5","pages":"160-167"},"PeriodicalIF":4.3,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13696858/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149277347","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Multiple myeloma: an overview of drug therapies and supportive care.","authors":"Jay Hocking","doi":"10.18773/austprescr.2026.044","DOIUrl":"10.18773/austprescr.2026.044","url":null,"abstract":"<p><p>Multiple myeloma is an incurable plasma cell malignancy. Treatment options have evolved significantly in recent years, improving survival and quality of life. Multiple myeloma is increasingly regarded as a chronic illness, particularly for patients with low-risk disease. For patients fit enough to undergo autologous stem cell transplantation, induction therapy with bortezomib (protease inhibitor), lenalidomide (immunomodulatory drug) and dexamethasone (corticosteroid), followed by transplantation, is the mainstay of treatment. Low-dose lenalidomide is continued after transplantation to help prolong remission. For transplant-ineligible patients, first-line therapy with the monoclonal antibody daratumumab, in combination with lenalidomide and dexamethasone, has significantly improved outcomes. Novel therapeutic options include bispecific T-cell engagers, which redirect a patient's immune cells to kill myeloma cells, and chimeric antigen receptor (CAR) T-cell therapy, where a patient's own T-cells are engineered to target and kill myeloma cells. However, high cost and uncertainty around optimal treatment sequencing remain challenges with the use of these newer treatment options. Patients receiving treatment for myeloma are at risk of treatment-related toxicities and infection, and have significant ongoing supportive care needs. A multidisciplinary approach involving primary care clinicians (e.g. general practitioners, pharmacists) and the treating haematology specialist is invaluable.</p>","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"49 6","pages":"188-193"},"PeriodicalIF":4.3,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13696861/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149277400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Glaucoma management in adults: an update.","authors":"Poh Wein Loh, Mark Walland, Alp Atik","doi":"10.18773/austprescr.2026.038","DOIUrl":"10.18773/austprescr.2026.038","url":null,"abstract":"<p><p>Glaucoma is a group of progressive optic neuropathies that cause optic nerve damage and visual field defects. It is typically asymptomatic until irreversible vision loss has occurred. Early detection relies on regular comprehensive eye examinations, with targeted case finding particularly important for people at increased risk. Lowering intraocular pressure is the only proven strategy to slow disease progression, and treatment should be individualised. Topical prostaglandin analogues (eye drops) are commonly used as first-line medical therapy, with once-daily dosing associated with improved adherence. Topical beta blockers may be added if the target intraocular pressure is not achieved or disease progression occurs. Patient adherence, eye drop technique and adverse effects should be reviewed regularly. Selective laser trabeculoplasty (a laser treatment that helps fluid drain out of the eye, thereby lowering intraocular pressure) is an effective first-line alternative to eye drops. Urgent referral to an ophthalmologist or emergency department is required for a suspected acute angle-closure attack. Symptoms include severe eye pain, headache, blurred vision, halos around lights, nausea and vomiting.</p>","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"49 5","pages":"182-187"},"PeriodicalIF":4.3,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13696860/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149277338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Delgocitinib for chronic hand eczema.","authors":"","doi":"10.18773/austprescr.2026.037","DOIUrl":"10.18773/austprescr.2026.037","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"49 5","pages":"202-203"},"PeriodicalIF":4.3,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13696864/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149277379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"COVID-19 vaccines move to the National Immunisation Program with revised eligibility.","authors":"","doi":"10.18773/austprescr.2026.042","DOIUrl":"10.18773/austprescr.2026.042","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"49 5","pages":"201"},"PeriodicalIF":4.3,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13696862/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149277352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Endometriosis and adenomyosis: diagnosis and management.","authors":"Sharinne B Crawford, Alissia Hui, Danielle Mazza","doi":"10.18773/austprescr.2026.041","DOIUrl":"10.18773/austprescr.2026.041","url":null,"abstract":"<p><p>Endometriosis and adenomyosis are common chronic gynaecological conditions with significant health and economic impacts. Endometriosis and adenomyosis present with diverse and overlapping symptoms and can coexist. Symptoms may include pelvic pain, dysmenorrhoea, heavy menstrual bleeding, fatigue and subfertility, contributing to impaired quality of life and reduced participation in work, education and social activities. General practitioners are often the first point of contact and play a critical role in early recognition, preliminary diagnosis, initiation of treatment and referral. The current Australian guideline supports clinical diagnosis and early management without waiting for surgical confirmation. First-line management includes analgesia and hormonal therapies, tailored to patient priorities, goals, fertility intention, comorbidities and concomitant medications. Timely investigation, person-centred care and appropriate referral are essential to reducing diagnostic delay, symptom burden and long-term impacts.</p>","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"49 5","pages":"168-173"},"PeriodicalIF":4.3,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13696865/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149277355","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Natasha Gorrie, Elyn Montgomery, Georgia McCaughan, Antonia S Carroll, Nicole K Bart
{"title":"Cardiac amyloidosis: recognition, diagnosis and management.","authors":"Natasha Gorrie, Elyn Montgomery, Georgia McCaughan, Antonia S Carroll, Nicole K Bart","doi":"10.18773/austprescr.2026.039","DOIUrl":"10.18773/austprescr.2026.039","url":null,"abstract":"<p><p>Cardiac amyloidosis is an under-recognised but treatable condition characterised by insoluble protein deposition in the heart and is associated with high morbidity and mortality. It is most commonly caused by transthyretin (known as transthyretin [ATTR] amyloidosis) but may also be caused by a plasma cell dyscrasia (known as light chain [AL] amyloidosis). Cardiac amyloidosis should be suspected in patients with heart failure and other suggestive features (e.g. carpal tunnel syndrome, peripheral and/or autonomic neuropathy), particularly in those aged over 65 years. Findings from a standard work-up for heart failure may raise the possibility of cardiac amyloidosis, such as unexplained cardiac biomarker elevation or left ventricular wall thickening on an echocardiogram. Early investigation can begin in primary care. Monoclonal protein testing is essential to exclude AL amyloidosis, which requires urgent haematology review and treatment. Standard heart failure assessment should also be undertaken if not already performed. Patients with suspected cardiac amyloidosis should be promptly referred to a cardiologist or amyloidosis centre for confirmatory testing, which, in most cases, can be done noninvasively. Treatment of ATTR includes disease-modifying therapies (tafamidis, vutrisiran) and heart failure management, predominantly with diuretics and sodium-glucose co-transporter 2 inhibitors. All patients with atrial fibrillation or atrial flutter should be anticoagulated regardless of CHA<sub>2</sub>DS<sub>2</sub>-VA score. Early recognition, timely referral and multidisciplinary care are essential to improve outcomes.</p>","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"49 5","pages":"174-181"},"PeriodicalIF":4.3,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13696863/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149277341","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Acne vulgaris: a clinical update.","authors":"Laxmi Iyengar, Belinda Welsh","doi":"10.18773/austprescr.2026.029","DOIUrl":"https://doi.org/10.18773/austprescr.2026.029","url":null,"abstract":"<p><p>Acne vulgaris is a chronic inflammatory condition with a substantial psychosocial burden. Early effective therapy reduces the risk of permanent scarring and mental health impacts. Combination topical therapy is recommended as initial and maintenance treatment for most patients (e.g. benzoyl peroxide and a topical retinoid). Topical antibiotics should not be used long-term, or as monotherapy, because of the risk of antibiotic resistance. Management has shifted away from prolonged oral antibiotic courses. If oral antibiotics are used, they should be time-limited (generally no more than 3 months) and paired with a non-antibiotic topical therapy. Oral isotretinoin is the most effective option for severe, scarring or treatment-resistant acne. Recent safety updates emphasise baseline and ongoing assessment of mental health, counselling about possible sexual adverse effects and stringent pregnancy prevention. The combined oral contraceptive and spironolactone are effective systemic options for women with persistent acne that can reduce reliance on repeated or prolonged antibiotic courses. Light-based therapies and physical therapies (e.g. comedone extraction) can be useful adjuncts, ideally accessed through dermatologists.</p>","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"49 4","pages":"138-144"},"PeriodicalIF":4.3,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13487665/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148801905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}